Related Experiment Video

Updated: Feb 22, 2026

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.2K

Fixed-duration vs continuous treatment for chronic lymphocytic leukemia in the CLL17 trial

Othman Al-Sawaf1

  • 1University Hospital, Cologne, Germany.

Clinical Advances in Hematology & Oncology : H&O
|February 20, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Related Experiment Videos

Last Updated: Feb 22, 2026

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.2K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Crossover Experiments01:16

Crossover Experiments

4.6K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
4.6K

Articles linked to this work by shared authors, journal, and citation graph.

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

European journal of haematology·2026

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Blood·2026

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

The New England journal of medicine·2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Blood·2025

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

Blood·2025

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Blood·2025

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical advances in hematology & oncology : H&O·2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.

Clinical advances in hematology & oncology : H&O·2026

From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity.

Obesity (Silver Spring, Md.)·2026

Targeting ERO1A enhances antitumor immune response by recruiting CD8+T cells and synergizing with PD-L1 blockade in liver cancer.

Cancer immunology research·2026

A Novel Hybrid Retroperitoneal Approach and Natural Orifice Specimen Extraction Surgery II for Surgical Treatment of Rectosigmoid Cancer.

Diseases of the colon and rectum·2026

Earlier bedtime misalignment is associated with increased severity of chemotherapy-induced hot flashes in premenopausal women with breast cancer.

Chronobiology international·2026

Metabolism-driven hepatotoxicity of 5-fluorouracil: molecular mechanisms and future therapeutic directions.

Drug metabolism reviews·2026

Coblation for Airway Pathologies: A Scoping Review.

The Laryngoscope·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us